Zyrtec-D added to Perrigo's private label

ALLEGAN, Mich. Perrigo on Thursday added Zyrtec-D to its private label offerings, following final Food and Drug Administration approval of Teva Pharmaceutical’s abbreviated new drug application for an over-the-counter version of cetirizine hydrochloride, pseudoephedrine hydrochloride extended-release tablets, 5 mg/120 mg.

According to Wolters Kluwer data, brand sales for the original prescription strength version of the product for the 12 months ending December 2007 were approximately $190 million.

“This approval and marketing agreement reflect our strategy to be first to market with the important products that make quality healthcare more affordable for our customers and drive value for our shareholders,” stated Perrigo’s chairman and chief executive officer Joseph Papa.

Perrigo expects to begin shipping the product in the next 90 days.

Login or Register to post a comment.